Search

OBJECTIVE: To evaluate the efficacy, safety and economy of icodextrin peritoneal dialysate based on rapid health technology assessment (HTA), so as to provide evidence-based medical-evidence information for clinical decision-makers. METHODS: PubMed, Embase, the Cochrane Library, CNKI, Wanfang Data and the official website of HTA institutions were searched systematically (the retrieval time was from the establishment of the database to Jun. 2022) to collect HTA reports, systematic review / Meta-analysis, and pharmacoeconomic studies related to icodextrin peritoneal dialysate. According to inclusion and exclusion criteria, two researchers independently screened articles, evaluated quality and extracted data, and qualitative analysis was performed on the data results. RESULTS: A total of 6 systematic review / Meta-analysis and 1 economic study were included. (1) In terms of effectiveness, compared with glucose peritoneal dialysis liquid, icodextrin peritoneal dialysate could significantly increase the ultrafiltration volume and peritoneal urea clearance rate, reduce free fatty acids and reduce the risk of ultrafiltration failure in patients during prolonged abdominal retention. (2) In terms of safety, the incidence of peritonitis associated with peritoneal dialysis and the incidence of total adverse drug reactions were not inferior to those of icodextrin peritoneal dialysate. (3) In terms of economics, icodextrin peritoneal dialysate was economical under the premise that it could delay the time of patients transferring from peritoneal dialysis to hemodialysis. CONCLUSIONS: Icodextrin peritoneal dialysate has good efficacy and safety in clinical treatment of peritoneal dialysis patients, but whether it is economic needs more relevant studies. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To evaluate the efficacy, safety and economy of icodextrin peritoneal dialysate based on rapid health technology assessment (HTA), so as to provide evidence-based medical-evidence information for clinical decision-makers. METHODS: PubMed, Embase, the Cochrane Library, CNKI, Wanfang Data and the official website of HTA institutions were searched systematically (the retrieval time was from the establishment of the database to Jun. 2022) to collect HTA reports, systematic review / Meta-analysis, and pharmacoeconomic studies related to icodextrin peritoneal dialysate. According to inclusion and exclusion criteria, two researchers independently screened articles, evaluated quality and extracted data, and qualitative analysis was performed on the data results. RESULTS: A total of 6 systematic review / Meta-analysis and 1 economic study were included. (1) In terms of effectiveness, compared with glucose peritoneal dialysis liquid, icodextrin peritoneal dialysate could significantly increase the ultrafiltration volume and peritoneal urea clearance rate, reduce free fatty acids and reduce the risk of ultrafiltration failure in patients during prolonged abdominal retention. (2) In terms of safety, the incidence of peritonitis associated with peritoneal dialysis and the incidence of total adverse drug reactions were not inferior to those of icodextrin peritoneal dialysate. (3) In terms of economics, icodextrin peritoneal dialysate was economical under the premise that it could delay the time of patients transferring from peritoneal dialysis to hemodialysis. CONCLUSIONS: Icodextrin peritoneal dialysate has good efficacy and safety in clinical treatment of peritoneal dialysis patients, but whether it is economic needs more relevant studies. [ABSTRACT FROM AUTHOR]